Spinal Cord Injury Market Summary
The Spinal Cord Injury market is undergoing a transformative shift, moving beyond symptomatic management toward disease-modifying and regenerative interventions. According to DelveInsight’s analysis, the SCI market across the 7MM (the US, EU4, UK, and Japan) was valued at approximately USD 350 million in 2025. Powered by the anticipated clinical entry of novel disease-modifying therapies and a growing diagnosed patient pool, the market is projected to expand at a robust CAGR of 18.3% through 2036.
The United States commands the largest market share, generating approximately USD 150 million in 2025 – roughly 44% of total 7MM revenue. By 2036, the US share is expected to climb to approximately 49%, anchored by a high diagnosed prevalent base of approximately 310,000 cases. Males represent nearly 80% of the affected population in the US, reflecting longstanding demographic patterns tied to vehicular accidents, workplace injuries, and sports-related trauma.
In EU4 and the UK, the combined market size was estimated at USD 160 million in 2025, accounting for the majority of non-US 7MM revenue. The region is projected to grow at a CAGR of 10.7% through 2036, supported by approximately 380,000 traumatic and 150,000 non-traumatic diagnosed prevalent SCI cases in 2025, with these figures expected to rise steadily over the forecast period (2026-2036). Japan accounted for approximately USD 50 million of total SCI market revenue in 2025. Falls represented the leading cause of injury in Japan, contributing approximately 60,000 cases, followed by vehicular accidents at around 20,000 cases. Japan’s market trajectory through 2036 will be heavily shaped by its aging population and increasing fall-related injury incidence.
Key Market Metrics:
- 2025 SCI Market Size (7MM): ~USD 350 million
- Growth Rate (2026-2036): 18.3% CAGR across the 7MM
- US Market (2025): ~USD 150 million
- EU4 + UK Market (2025): ~USD 160 million
- Japan Market (2025): ~USD 50 million
Spinal Cord Injury (SCI) Insights and Trends
Advances in diagnostic pathways and patient stratification, along with heightened awareness of both traumatic and non-traumatic SCI subtypes, are enabling earlier identification and more timely clinical intervention, particularly in acute injury settings. The Spinal Cord Injury market insight reflects a rapidly maturing clinical landscape where mechanistic diversity in the pipeline – spanning neuroprotective, anti-inflammatory, and regenerative modalities – is expected to drive long-term market innovation.
The SCI pipeline approaching 2026 is particularly focused on neuroprotective and regenerative approaches. Key players actively advancing pipeline assets include:
- AbbVie – elezanumab (ABT-555), expected to enter the US market by 2028
- Mitsubishi Tanabe Pharma America
- Neuroplast
- Kringle Pharma – oremepermin alfa
Safety, tolerability, and adherence challenges – particularly in the acute care setting and among patients managing long-term paralysis-related comorbidities – remain key determinants of real-world treatment effectiveness and commercial uptake.
Discover the Full Spinal Cord Injury Market Report to Unlock In-Depth Competitive and Clinical Intelligence Today.
SCI Therapies
Three prominent therapies shaping the evolving treatment landscape include:
- STEMIRAC (Nipro Corporation) – autologous mesenchymal stem cell therapy
- Oremepermin alfa (Kringle Pharma) – evaluated in Phase III for acute SCI
- Elezanumab / ABT-555 (AbbVie) – anticipated US market entry by 2028
Spinal Cord Injury Overview and Diagnosis
SCI refers to a sudden disruption of the spinal cord’s neuronal tissue within the spinal canal resulting from trauma, disease, or degeneration. Depending on the level and type of damage, SCI can manifest as upper or lower motor neuron lesions, leading to varying degrees of motor, sensory, and autonomic dysfunction – effects that may be temporary or permanent.
Effective SCI management requires:
- Precise clinical examination and neurological classification
- Detailed radiological assessments of the vertebral column
- Multidisciplinary treatment strategies encompassing immediate medical intervention, surgical procedures, pharmacological therapies, and rehabilitation programs
Spinal Cord Injury Unmet Needs
Despite incremental progress, significant gaps persist between current standards of care and ideal patient outcomes. Key unmet needs in the Spinal Cord Injury market research landscape include:
- Need for effective neuroprotective strategies to limit secondary injury cascades
- Policies addressing financial barriers and improving access to rehabilitation services
- Need for personalized medicine tailored to injury level, subtype, and patient profile
- Better solutions for long-term care and rehabilitation continuity
- Improved patient stratification tools for appropriate therapy selection
Spinal Cord Injury Epidemiology
Key Epidemiological Findings (2025):
- Approximately 1 million total diagnosed prevalent SCI cases across the 7MM in 2025, expected to rise by 2036
- ~19,000 acute (incident) SCI cases recorded in the US in 2025
- ~300,000 diagnosed prevalent SCI cases in the US in 2025, with an estimated 250,000 male and 60,000 female cases
- ~500,000 diagnosed prevalent SCI cases in EU4 and the UK combined in 2025
- In the UK: ~93,000 traumatic and ~13,000 non-traumatic diagnosed prevalent SCI cases in 2025
- In Japan (2025 case distribution by cause):
- Falls: ~55%
- Vehicular accidents: ~20%
- Violence, sports injuries, and medical/surgical causes: ~5% each
- Other factors: ~10%
Spinal Cord Injury Approved Therapies
STEMIRAC – Nipro Corporation
STEMIRAC is an autologous mesenchymal stem cell therapy developed by Nipro Corporation for traumatic SCI. The therapy involves isolating mesenchymal stem cells from the patient’s bone marrow, culturing them in vitro, and cryopreserving them for future use. It aims to improve neurological symptoms and motor functions associated with spinal cord injuries. In 2018, STEMIRAC became the world’s first stem cell therapy to receive conditional approval from Japan’s PMDA for the treatment of neurological symptoms associated with SCI.
Spinal Cord Injury Drug Updates – Recent Developments
- February 2024: Kringle Pharma reported topline results from its Phase III study evaluating oremepermin alfa for acute spinal cord injury
- July 2023: Nipro Corporation initiated a corporate clinical trial for chronic SCI, expanding the indication of STEMIRAC beyond subacute to chronic injury
- February 2016: STEMIRAC received SAKIGAKE Breakthrough Designation in Japan, accelerating development for regenerative medical products targeting neurological symptoms associated with SCI
- As of early 2026: The December 2025 full approval deadline for STEMIRAC has passed without a confirmed transition to unconditional approval, introducing uncertainty around commercialization timelines
Spinal Cord Injury Market Outlook
SCI is a devastating and life-altering neurological condition resulting from traumatic or non-traumatic damage to the spinal cord, leading to partial or complete loss of motor, sensory, and autonomic function. The absence of a curative treatment, the high lifetime cost of care, and the complexity of spinal cord regeneration make SCI one of the most challenging conditions in modern medicine.
Key Marketed Therapies Shaping Current Management:
- Pregabalin (LYRICA): The sole FDA-approved medication for neuropathic pain associated with SCI; targets alpha2-delta subunits of voltage-gated calcium channels, modulating pain pathways without affecting GABA receptors, sodium channels, or opiate receptors
- Methylprednisolone: An intravenous corticosteroid administered shortly after injury to target acute inflammation; its widespread use has become contentious due to potential side effects, leading to declining recommendations as routine standard of care
- Tramadol: A low-affinity μ-opioid receptor agonist that also inhibits serotonin and norepinephrine reuptake, offering analgesic relief with a comparatively reduced opioid side-effect burden in chronic SCI pain management
- Gabapentin: Binds to the α2δ subunit of voltage-gated calcium channels, widely used in multimodal pain management regimens for SCI patients
- Cannabinoids (THC/CBD): Modulate pain perception and reduce neuroinflammation via CB1 and CB2 receptor binding, increasingly positioned as adjunctive options in SCI symptom management
- STEMIRAC: World’s first conditionally approved stem cell therapy for SCI-associated neurological symptoms (Japan PMDA, 2018); full approval status remains pending as of early 2026
The Spinal Cord Injury market trends point toward a dual-track evolution: continued refinement of symptomatic management alongside a late-stage pipeline that holds genuine disease-modifying promise.
Spinal Cord Injury Drug Uptake
Current therapies primarily emphasize rehabilitation and symptom management, underscoring a significant unmet need for treatments promoting nerve regeneration and functional recovery.
The forecast period (2026-2036) is expected to witness a meaningful shift in this dynamic:
- Elezanumab (ABT-555) is anticipated to enter the US market in 2028, generating significant revenue during its launch year
- By 2036, elezanumab’s revenue contribution is expected to rise substantially, driven by a medium-fast uptake trajectory
- Repurposing of existing drugs alongside novel therapeutic agents is expected to progressively fill critical gaps in acute and chronic SCI management
- Improved patient stratification and clinical trial refinement will play a pivotal role in determining real-world uptake and payer acceptance
Access Exclusive Spinal Cord Injury Market Insights and Forecast Data to Accelerate Your Strategic Decision-Making Now
Conclusion
The SCI market stands at an inflection point, transitioning from largely palliative care to a landscape shaped by regenerative and neuroprotective innovation. With a projected CAGR of 18.3% through 2036, rising epidemiological burden, and a diverse late-stage pipeline, stakeholders across pharma, biotech, and healthcare delivery are increasingly focused on SCI as a priority therapeutic area. Addressing unmet needs in personalized medicine, long-term rehabilitation, and acute neuroprotection will be critical to sustaining this momentum and translating clinical advances into meaningful patient outcomes.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
